Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TD-8236
- Development stage
- Phase 2
- Lead developer
- Theravance Biopharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TD-8236 is an investigational, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor developed by Theravance Biopharma for the treatment of respiratory diseases, primarily asthma. It is a small molecule drug designed to target airway inflammation in the lungs with minimal systemic exposure. By inhibiting all JAK family enzymes (pan-JAK), it aims to modulate a broad range of cytokines implicated in both Th2-high and Th2-low asthma phenotypes. The drug was evaluated in phase 1 and phase 2 clinical trials as an anti-inflammatory and antiasthmatic agent but its development for asthma has been suspended[2][3][4][7][8].
- Other names
- TD-8236TD8236TD 8236
02
Targets
Beyond the preview
Go deeper on TD-8236.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TD-8236.